Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab and Tuvusertib in Advanced Urothelial Carcinoma
NCT06424717Phase 2Withdrawn
- Sponsor
- EMD Serono
- Start
- Aug 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of tuvusertib in urothelial carcinoma (UC), sponsored by EMD Serono. Planned start Aug 2024; status: withdrawn.
02
Drugs
tuvusertib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06424717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06424717.